Diagnostic performance of <sup>68</sup>Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.
Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U. · 2017
Read Diagnostic performance of <sup>68</sup>Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. by Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5486817.txt.
Description
Afshar-Oromieh and co-authors report a large imaging study in the European Journal of Nuclear Medicine and Molecular Imaging. It tests a PSMA-targeted PET scan in men whose prostate cancer returned. Standard scans often miss such recurrences. The tracer homes in on a protein that prostate tumors display heavily. The team reviewed scans from 1,007 patients at one center.
At least one suspicious lesion showed up in 79.5 percent of patients, they report. Detection rose clearly with PSA level and hormone therapy use. Tumor grade showed only a weak, non-firm trend. Age, injected dose, and PSA speed measures did not matter. The scan looks strong for planning salvage care.
Catalog record
| CREATOR | Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |